ATLANTA, Feb. 23, 2026 — MiRus announced U.S. FDA 510(k) clearance and commercial launch of the IO™ Expandable Wedge Osteotomy System, an advanced orthopedic implant engineered to enhance intraoperative precision and adjustability in foot and ankle osteotomy procedures. Built on the company’s proprietary MoRe® Superalloy platform and powered by the MoRe Expansion Engine, the system introduces controlled, incremental expandability to Evans osteotomies, a surgical technique traditionally dependent on static wedge implants.
Science Significance
The IO Expandable Wedge Osteotomy System represents a meaningful advancement in orthopedic biomaterials engineering and surgical biomechanics. Conventional osteotomy wedges rely on fixed dimensions selected preoperatively, limiting intraoperative flexibility. In contrast, the expandable implant allows surgeons to perform real-time anatomical correction through gradual distraction after placement. This dynamic capability enables precise evaluation of hindfoot alignment, forefoot abduction, and multiplanar balance before final fixation. The integration of MoRe Superalloy — engineered for high fatigue resistance, structural strength, and adaptive flexibility — enhances implant durability while supporting biomechanical stability. Additionally, the device accommodates bone graft placement, promoting biological integration and osteotomy healing, thereby advancing surgical outcomes in complex reconstructive foot procedures.
Regulatory Significance
FDA 510(k) clearance confirms that the IO Expandable Wedge Osteotomy System meets U.S. regulatory standards for safety, performance, and clinical usability. The clearance pathway validates substantial equivalence to predicate orthopedic devices while recognizing technological innovation in implant design. Regulatory approval also supports broader adoption across ambulatory surgical centers and hospital orthopedic programs. As expandable implant systems incorporate advanced materials and mechanical expansion mechanisms, regulatory evaluation ensures device reliability, sterilization integrity, and intraoperative safety performance — all critical to maintaining compliance within orthopedic surgical practice.
Business Significance
Advertisement
From a commercial standpoint, the clearance strengthens MiRus’ strategic positioning within the extremities and orthopedic reconstruction market. The system expands the company’s portfolio of expandable implant technologies, complementing its ultra-thin plating systems and trauma fixation solutions. By introducing adjustable osteotomy implants, MiRus addresses a segment historically characterized by limited innovation. The platform’s adaptability and surgeon-driven correction capabilities enhance competitive differentiation while opening new revenue channels across foot and ankle surgery markets. Continued expansion of the extremities portfolio signals the company’s commitment to scalable growth in orthopedic biomaterials and procedural solutions.
Patients’ Significance
For patients undergoing corrective foot and ankle procedures — particularly those with adult-acquired flatfoot or complex multiplanar deformities — the technology may translate into improved surgical precision and recovery outcomes. The ability to fine-tune correction intraoperatively supports enhanced alignment accuracy, structural balance, and long-term functional stability. Improved implant positioning may reduce revision risk, optimize gait restoration, and support faster rehabilitation. As reconstructive orthopedic procedures evolve toward personalized surgical solutions, expandable implants offer patients more tailored anatomical correction.
Policy Significance
The clearance also aligns with broader healthcare policy priorities promoting medical device innovation, surgical precision technologies, and advanced biomaterials development. Regulators and healthcare systems are increasingly supporting technologies that enhance procedural efficiency while improving patient outcomes. Expandable orthopedic implants reflect ongoing investment in minimally invasive reconstruction, value-based surgical care, and implant longevity — all key considerations in modern healthcare infrastructure planning and reimbursement frameworks.
The FDA clearance of the IO Expandable Wedge Osteotomy System marks a pivotal milestone in orthopedic implant innovation. By combining advanced superalloy biomaterials with real-time surgical adjustability, MiRus is redefining precision in foot and ankle osteotomy reconstruction. As demand grows for adaptable, surgeon-controlled implant technologies, expandable platforms such as IO are poised to play a central role in improving alignment accuracy, surgical reproducibility, and long-term patient outcomes across complex orthopedic procedures.
Source: MiRus press release
